Search

Your search keyword '"López Jaramillo, CA"' showing total 7 results
Start Over Author "López Jaramillo, CA"
7 results on '"López Jaramillo, CA"'

1. Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report

Author

Manchia, M, Adli, M, Akula, N, Ardau, R, Aubry, JM, Backlund, L, Banzato, CEM, Baune, BT, Bellivier, F, Bengesser, S, Biernacka, JM, Brichant-Petitjean, C, Bui, E, Calkin, CV, Cheng, ATA, Chillotti, C, Cichon, S, Clark, S, Czerski, PM, Dantas, C, Del Zompo, M, DePaulo, JR, Detera-Wadleigh, SD, Etain, B, Falkai, P, Frisén, L, Frye, MA, Fullerton, J, Gard, S, Garnham, J, Goes, FS, Grof, P, Gruber, O, Hashimoto, R, Hauser, J, Heilbronner, U, Hoban, R, Hou, L, Jamain, S, Kahn, JP, Kassem, L, Kato, T, Kelsoe, JR, Kittel-Schneider, S, Kliwicki, S, Kuo, PH, Kusumi, I, Laje, G, Lavebratt, C, Leboyer, M, Leckband, SG, López Jaramillo, CA, Maj, M, Malafosse, A, Martinsson, L, Masui, T, Mitchell, PB, Mondimore, F, Monteleone, P, Nallet, A, Neuner, M, Novák, T, O'Donovan, C, Ösby, U, Ozaki, N, Perlis, RH, Pfennig, A, Potash, JB, Reich-Erkelenz, D, Reif, A, Reininghaus, E, Richardson, S, Rouleau, GA, Rybakowski, JK, Schalling, M, Schofield, PR, Schubert, OK, Schweizer, B, Seemüller, F, Grigoroiu-Serbanescu, M, Severino, G, Seymour, LR, Slaney, C, Smoller, JW, Squassina, A, Stamm, T, Steele, J, Stopkova, P, Tighe, SK, Tortorella, A, Turecki, G, Wray, NR, Wright, A, Zandi, PP, Zilles, D, Bauer, M, Rietschel, M, McMahon, FJ, Schulze, TG, Alda, M, Manchia, M, Adli, M, Akula, N, Ardau, R, Aubry, JM, Backlund, L, Banzato, CEM, Baune, BT, Bellivier, F, Bengesser, S, Biernacka, JM, Brichant-Petitjean, C, Bui, E, Calkin, CV, Cheng, ATA, Chillotti, C, Cichon, S, Clark, S, Czerski, PM, Dantas, C, Del Zompo, M, DePaulo, JR, Detera-Wadleigh, SD, Etain, B, Falkai, P, Frisén, L, Frye, MA, Fullerton, J, Gard, S, Garnham, J, Goes, FS, Grof, P, Gruber, O, Hashimoto, R, Hauser, J, Heilbronner, U, Hoban, R, Hou, L, Jamain, S, Kahn, JP, Kassem, L, Kato, T, Kelsoe, JR, Kittel-Schneider, S, Kliwicki, S, Kuo, PH, Kusumi, I, Laje, G, Lavebratt, C, Leboyer, M, Leckband, SG, López Jaramillo, CA, Maj, M, Malafosse, A, Martinsson, L, Masui, T, Mitchell, PB, Mondimore, F, Monteleone, P, Nallet, A, Neuner, M, Novák, T, O'Donovan, C, Ösby, U, Ozaki, N, Perlis, RH, Pfennig, A, Potash, JB, Reich-Erkelenz, D, Reif, A, Reininghaus, E, Richardson, S, Rouleau, GA, Rybakowski, JK, Schalling, M, Schofield, PR, Schubert, OK, Schweizer, B, Seemüller, F, Grigoroiu-Serbanescu, M, Severino, G, Seymour, LR, Slaney, C, Smoller, JW, Squassina, A, Stamm, T, Steele, J, Stopkova, P, Tighe, SK, Tortorella, A, Turecki, G, Wray, NR, Wright, A, Zandi, PP, Zilles, D, Bauer, M, Rietschel, M, McMahon, FJ, Schulze, TG, and Alda, M

Abstract

Objective:The assessment of response to lithium maintenance treatment in bipolar disorder (BD) is complicated by variable length of treatment, unpredictable clinical course, and often inconsistent compliance. Prospective and retrospective methods of assessment of lithium response have been proposed in the literature. In this study we report the key phenotypic measures of the "Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder" scale currently used in the Consortium on Lithium Genetics (ConLiGen) study.Materials and Methods:Twenty-nine ConLiGen sites took part in a two-stage case-vignette rating procedure to examine inter-rater agreement [Kappa (κ)] and reliability [intra-class correlation coefficient (ICC)] of lithium response. Annotated first-round vignettes and rating guidelines were circulated to expert research clinicians for training purposes between the two stages. Further, we analyzed the distributional properties of the treatment response scores available for 1,308 patients using mixture modeling.Results:Substantial and moderate agreement was shown across sites in the first and second sets of vignettes (κ = 0.66 and κ = 0.54, respectively), without significant improvement from training. However, definition of response using the A score as a quantitative trait and selecting cases with B criteria of 4 or less showed an improvement between the two stages (ICC1 = 0.71 and ICC2 = 0.75, respectively). Mixture modeling of score distribution indicated three subpopulations (full responders, partial responders, non responders).Conclusions:We identified two definitions of lithium response, one dichotomous and the other continuous, with moderate to substantial inter-rater agreement and reliability. Accurate phenotypic measurement of lithium response is crucial for the ongoing ConLiGen pharmacogenomic study.

Published
2013

2. Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report

Author

J. Raymond DePaulo, Martin Alda, Alfonso Tortorella, Susan G. Leckband, Jean-Michel Aubry, James B. Potash, Clara Brichant-Petitjean, Layla Kassem, Joanna Hauser, Tomas Novak, David Zilles, Claire O'Donovan, Rebecca Hoban, Sarah Kittel-Schneider, Claire Slaney, Lena Backlund, Peter Falkai, Andrew T. A. Cheng, John R. Kelsoe, Andrea Pfennig, Janice M. Fullerton, Marcella Rietschel, Caterina Chillotti, Stéphane Jamain, Elise Bui, Po-Hsiu Kuo, Alessio Squassina, Claudio E. M. Banzato, Joanna M. Biernacka, Lisa R. Seymour, Naomi R. Wray, Ichiro Kusumi, Thomas Stamm, Fernando S. Goes, Audrey Nallet, Sarah K. Tighe, Giovanni Severino, Jean-Pierre Kahn, Maria Neuner, Nirmala Akula, Norio Ozaki, Francis J. McMahon, Frank Bellivier, Andreas Reif, Ryota Hashimoto, Barbara W. Schweizer, Palmiero Monteleone, Florian Seemüller, Urs Heilbronner, Sevilla D. Detera-Wadleigh, Pavla Stopkova, Martin Schalling, Julie Garnham, Sébastien Gard, Mark A. Frye, Eva Z. Reininghaus, Lina Martinsson, Urban Ösby, Maria Grigoroiu-Serbanescu, Sara Richardson, Tadafumi Kato, Marion Leboyer, Catharina Lavebratt, Piotr M. Czerski, Scott R. Clark, Daniela Reich-Erkelenz, Sebastian Kliwicki, Guy A. Rouleau, Oliver Gruber, Gonzalo Laje, Adam Wright, Gustavo Turecki, Roy H. Perlis, Takuya Masui, Mirko Manchia, Bernhard T. Baune, Mazda Adli, Michael Bauer, Sven Cichon, Frank Mondimore, Bruno Etain, Philip B. Mitchell, Thomas G. Schulze, Peter P. Zandi, Raffaella Ardau, Peter R. Schofield, Susanne Bengesser, Liping Hou, Janusz K. Rybakowski, Mario Maj, Clarissa de Rosalmeida Dantas, Louise Frisén, O. Schubert, Carlos Jaramillo, Maria Del Zompo, Paul Grof, Cynthia V. Calkin, Jo Steele, Jordan W. Smoller, Alain Malafosse, Manchia, M, Adli, M, Akula, N, Ardau, R, Aubry, Jm, Backlund, L, Banzato, Ce, Baune, Bt, Bellivier, F, Bengesser, S, Biernacka, Jm, Brichant Petitjean, C, Bui, E, Calkin, Cv, Cheng, At, Chillotti, C, Cichon, S, Clark, S, Czerski, Pm, Dantas, C, Zompo, Md, Depaulo, Jr, Detera Wadleigh, Sd, Etain, B, Falkai, P, Frisén, L, Frye, Ma, Fullerton, J, Gard, S, Garnham, J, Goes, F, Grof, P, Gruber, O, Hashimoto, R, Hauser, J, Heilbronner, U, Hoban, R, Hou, L, Jamain, S, Kahn, Jp, Kassem, L, Kato, T, Kelsoe, Jr, Kittel Schneider, S, Kliwicki, S, Kuo, Ph, Kusumi, I, Laje, G, Lavebratt, C, Leboyer, M, Leckband, Sg, López Jaramillo, Ca, Maj, Mario, Malafosse, A, Martinsson, L, Masui, T, Mitchell, Pb, Mondimore, F, Monteleone, P, Nallet, A, Neuner, M, Novák, T, O'Donovan, C, Osby, U, Ozaki, N, Perlis, Rh, Pfennig, A, Potash, Jb, Reich Erkelenz, D, Reif, A, Reininghaus, E, Richardson, S, Rouleau, Ga, Rybakowski, Jk, Schalling, M, Schofield, Pr, Schubert, Ok, Schweizer, B, Seemüller, F, Grigoroiu Serbanescu, M, Severino, G, Seymour, Lr, Slaney, C, Smoller, Jw, Squassina, A, Stamm, T, Steele, J, Stopkova, P, Tighe, Sk, Tortorella, Alfonso Antonio Vincenzo, Turecki, G, Wray, Nr, Wright, A, Zandi, Pp, Zilles, D, Bauer, M, Rietschel, M, Mcmahon, Fj, Schulze, Tg, Alda, M., Department of Psychiatry, Dalhousie University [Halifax], Department of Psychiatry and Psychotherapy, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Human Genetics Branch, National Institutes of Health [Bethesda] (NIH)-National Institute of Mental Health (NIMH), Unit of Clinical Pharmacology, University-Hospital of Cagliari, Department of Mental Health and Psychiatry, University Hospital of Geneva, Trinity College Dublin-St. James's Hospital, University of Campinas [Campinas] (UNICAMP), University of Adelaide, Pôle de Psychiatrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Medical University Graz, Mayo Clinic, Division of Epidemiology and Genetics, Academia Sinica-Institute of Biomedical Sciences (ICB/USP), Universidade de São Paulo (USP)-Universidade de São Paulo (USP), Department of Genomics, Life and Brain Center, University of Bonn, Psychiatric Genetic Unit, Poznan University of Medical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, University of Homburg, Genetics of Mental Illness and Brain Function, Neuroscience Research Australia, Service de psychiatrie adulte, Université Bordeaux Segalen - Bordeaux 2-Hôpital Charles Perrens-Centre Expert Trouble Bipolaire, Mood Disorders Center of Ottawa (MDCO), University of Ottawa [Ottawa], University of Toronto, Georg-August-University [Göttingen], Osaka University Graduate School of Medicine, University of California [San Diego] (UC San Diego), University of California-University of California, Service de Psychiatrie et Psychologie Clinique, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Hôpital Jeanne-d'Arc, Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science [Wako] (RIKEN CBS), RIKEN - Institute of Physical and Chemical Research [Japon] (RIKEN)-RIKEN - Institute of Physical and Chemical Research [Japon] (RIKEN), Mental Health Sciences Unit, University College of London [London] (UCL), Department of Adult Psychiatry, Institute of Epidemiology and Preventive Medicine, National Taiwan University [Taiwan] (NTU), Hokkaido University Graduate School of Medicine, Molecular Medicine and Surgery department, Karolinska Institutet [Stockholm], Center for Molecular Medicine, Karolinska University Hospital [Stockholm], Department of Pharmacy, Veterans Affairs San Diego Healthcare System, Skaggs School of Pharmacy and Pharmaceutical Sciences [San Diego], University of Antioquia, University of Napoli, School of Psychiatry, University of New South Wales [Sydney] (UNSW)-Black Dog Institute, Prague Psychiatric Center, University of Prague, Fujita Health University School of Medicine, Nagoya University Graduate School of Medicine, Harvard Medical School [Boston] (HMS)-Massachusetts General Hospital [Boston], Technische Universität Dresden = Dresden University of Technology (TU Dresden), University of Iowa [Iowa City], Center of Excellence in Neuroscience, CHU de Montréal, Department of Medicine, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR CHUM), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM)-Université de Montréal (UdeM)-Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM)-Université de Montréal (UdeM), Biometric Psychiatric Genetics Research Unit, Alexandru Obregia Psychiatric Hospital, McGill Group for Suicide Studies, Douglas Mental Health University Institute, Queensland Brain Institute, University of Queensland [Brisbane], Department of Mental Health, Johns Hopkins Bloomberg School of Public Health [Baltimore], Johns Hopkins University (JHU)-Johns Hopkins University (JHU), Department of Genetic Epidemiology in Psychiatry [Mannhein], Universität Heidelberg [Heidelberg]-Central Institute of Mental Health Mannheim, The work on assessment of lithium response has been supported by a grant from Canadian Institutes of Health Research #64410 to MA. MG-S was supported by Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii (UEFISCDI), Bucharest, Romania (grant no. 89/2012). JMA and AN were supported by a grant from the Swiss National Foundation (#32003B_125469/1 to JM Aubry). ConLiGen is in part supported by funds from the Intramural Research Program of the National Institute of Mental Health (NIMH) at the National Institutes of Health (NIH), Department of Health and Human Services, United States Government, Aubry, Jean-Michel, Universidade Estadual de Campinas = University of Campinas (UNICAMP), Universidade de São Paulo = University of São Paulo (USP)-Universidade de São Paulo = University of São Paulo (USP), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Georg-August-University = Georg-August-Universität Göttingen, University of California (UC)-University of California (UC), Guellaen, Georges, Université Bordeaux Segalen - Bordeaux 2-Centre hospitalier Charles Perrens [Bordeaux]-Centre Expert Trouble Bipolaire, and Ikeda, Kazutaka

Subjects
Male, Bipolar Disorder, Lithium (medication), Psychometrics, Psychopharmacology, Epidemiology, International Cooperation, lcsh:Medicine, Lithium, Maintenance Treatment, ConLiGen, ddc:616.89, 0302 clinical medicine, Antimanic Agents, Psychology, lcsh:Science, Reliability (statistics), Psychiatry, Genetics, 0303 health sciences, Multidisciplinary, ASSOCIATION, Genomics, Pharmacoepidemiology, 3. Good health, Mental Health, Phenotype, Treatment Outcome, MAPPING SUSCEPTIBILITY GENES, Behavioral Pharmacology, RELIABILITY, Lithium Compounds, Medicine, Female, Research Article, medicine.drug, Drugs and Devices, MAPPING SUSCEPTIBILITY GENES, PROPHYLACTIC LITHIUM, OBSERVER AGREEMENT, MOOD DISORDERS, ONSET, ASSOCIATION, RELIABILITY, MORTALITY, ILLNESS, AGE, ILLNESS, PROPHYLACTIC LITHIUM, 03 medical and health sciences, AGE, Neuropharmacology, Genomic Medicine, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Genome-Wide Association Studies, medicine, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, Bipolar disorder, ddc:610, Biology, 030304 developmental biology, Mood Disorders, business.industry, MORTALITY, lcsh:R, Computational Biology, Reproducibility of Results, Models, Theoretical, medicine.disease, OBSERVER AGREEMENT, Mood disorders, Pharmacogenetics, Therapies, ONSET, lcsh:Q, Pharmacogenomics, business, 030217 neurology & neurosurgery, Kappa
Abstract

Objective: The assessment of response to lithium maintenance treatment in bipolar disorder (BD) is complicated by variable length of treatment, unpredictable clinical course, and often inconsistent compliance. Prospective and retrospective methods of assessment of lithium response have been proposed in the literature. In this study we report the key phenotypic measures of the "Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder" scale currently used in the Consortium on Lithium Genetics (ConLiGen) study. Materials and Methods: Twenty-nine ConLiGen sites took part in a two-stage case-vignette rating procedure to examine inter-rater agreement [Kappa (\(\kappa\))] and reliability [intra-class correlation coefficient (ICC)] of lithium response. Annotated first-round vignettes and rating guidelines were circulated to expert research clinicians for training purposes between the two stages. Further, we analyzed the distributional properties of the treatment response scores available for 1,308 patients using mixture modeling. Results: Substantial and moderate agreement was shown across sites in the first and second sets of vignettes (\(\kappa\) = 0.66 and \(\kappa\) = 0.54, respectively), without significant improvement from training. However, definition of response using the A score as a quantitative trait and selecting cases with B criteria of 4 or less showed an improvement between the two stages (\(ICC_1 = 0.71\) and \(ICC_2 = 0.75\), respectively). Mixture modeling of score distribution indicated three subpopulations (full responders, partial responders, non responders). Conclusions: We identified two definitions of lithium response, one dichotomous and the other continuous, with moderate to substantial inter-rater agreement and reliability. Accurate phenotypic measurement of lithium response is crucial for the ongoing ConLiGen pharmacogenomic study.

Published
2013

3. Looking beyond psychosocial adversity and sex: Clinical factors associated with ADHD and other psychiatric disorders in a non-Caucasian sample of high-risk siblings.

Author

Palacio-Ortiz JD, Palacios-Cruz L, Martínez-Zamora M, Valencia-Echeverry J, Macias-Duran J, and López-Jaramillo CA

Subjects
Humans, Female, Male, Colombia, Cross-Sectional Studies, Child, Adolescent, Sex Factors, Adverse Childhood Experiences statistics & numerical data, Risk Factors, Attention Deficit Disorder with Hyperactivity, Siblings psychology, Mental Disorders epidemiology
Abstract

This study examined the association of clinical factors, independent of sex and high psychosocial adversity (HPAd), with the presence of ADHD or other mental disorders, specifically within a middle-income country with a non-Caucasian population. A multi-centric cross-sectional study was conducted in three sites in Colombia. Our study recruited trios of an ADHD proband, one sibling, and one parent. We used valid instruments for assessing parents and siblings. The sample included 223 siblings, an average age of 12.3 (SD 3.9), and 51.1% Females. The ADHD recurrence risk ratio (λ) was 12. The clinical factors mainly associated with the presence of ADHD, independent of sex and HPAd, were 1) Pregnancy and childbirth complications, 2) Delayed psychomotor development, 3) Temperament, and 4) Sleep disturbances. Our research showed that, independently of HPAd and the male sex, there were other clinical factors associated with ADHD and other psychiatric disorders in this population. These findings need to be replicated in similar populations globally., Competing Interests: Declaration of competing interest None., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)

Published
2024
Full Text
View/download PDF

5. Correlation between cognitive performance and structural neuroanatomy in patients with type I bipolar affective disorder treated with and without lithium.

Author

Díaz Ortiz AC, Vargas Upeguí C, Zapata Ospina JP, Aguirre Acevedo DC, Pineda Zapata JA, and López Jaramillo CA

Subjects
Cognition, Cross-Sectional Studies, Humans, Lithium therapeutic use, Mood Disorders, Neuroanatomy, Bipolar Disorder drug therapy
Abstract

Introduction: Lithium treatment of bipolar disorder (BD) has been associated with less cognitive impairment and fewer changes in structural brain anatomy compared to other treatments. However, the studies are heterogeneous and few assess whether these effects are related. The objective of this study was to evaluate and relate cognitive performance and structural neuroanatomy in patients treated with and without lithium., Methods: Cross-sectional study that included 48 subjects with BD-I, of which 22 were treated with lithium and 26 without lithium. Performance was assessed on Wechsler III (WAIS III), TMT A and B (Trial Making Test) neuropsychological tests, California verbal learning test (CVLT), Rey complex figure test and Wisconsin card sorting test. Brain structures obtained by magnetic resonance imaging (MRI) were evaluated. The standardised mean difference (SMD) between both groups was calculated, adjusted for confounding variables using a propensity score, and the Spearman correlation coefficient (ρ) was used to assess the relationship between cognitive performance and neuroanatomical regions., Results: Compared to the group without lithium, the group with lithium had fewer perseverative errors in the Wisconsin test (SMD = -0.69) and greater left and right cortical areas (SMD = 0.85; SMD = 0.92); greater surface area in the left anterior cingulate (SMD = 1.32), right medial orbitofrontal cortex (SMD = 1.17), right superior frontal gyrus (SMD = 0.82), and right and left precentral gyrus (SMD = 1.33; SMD = 0.98); greater volume of the right amygdala (SMD = 0.57), right hippocampus (SMD = 0.66), right putamen (SMD = 0.87) and right thalamus (SMD = .67). In the lithium group, a correlation was found with these errors and the thickness of the left precentral gyrus (ρ = -0.78), the volume of the right thalamus (ρ = -0.44), and the right amygdala (ρ = 0.6)., Conclusions: The lithium group had better cognitive flexibility and greater dimension in some frontal and subcortical cortical regions. Furthermore, there was a moderate to high correlation between performance in this executive function and the thickness of the right precentral gyrus, and the volumes of the thalamus and the right amygdala. These findings could suggest a neuroprotective effect of lithium., (Copyright © 2020 Asociación Colombiana de Psiquiatría. Published by Elsevier España, S.L.U. All rights reserved.)

Published
2022
Full Text
View/download PDF

6. Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder.

Author

Reinbold CS, Forstner AJ, Hecker J, Fullerton JM, Hoffmann P, Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, Ardau R, Arias B, Backlund L, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Birner A, Marie-Claire C, Cervantes P, Chen GB, Chen HC, Chillotti C, Clark SR, Colom F, Cousins DA, Cruceanu C, Czerski PM, Dayer A, Étain B, Falkai P, Frisén L, Gard S, Garnham JS, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Herms S, Jamain S, Jiménez E, Kahn JP, Kassem L, Kittel-Schneider S, Kliwicki S, König B, Kusumi I, Lackner N, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, López Jaramillo CA, MacQueen G, Manchia M, Martinsson L, Mattheisen M, McCarthy MJ, McElroy SL, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Ösby U, Ozaki N, Perlis RH, Pfennig A, Reich-Erkelenz D, Rouleau GA, Schofield PR, Schubert KO, Schweizer BW, Seemüller F, Severino G, Shekhtman T, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Smoller JW, Squassina A, Stamm TJ, Stopkova P, Tighe SK, Tortorella A, Turecki G, Volkert J, Witt SH, Wright AJ, Young LT, Zandi PP, Potash JB, DePaulo JR, Bauer M, Reininghaus E, Novák T, Aubry JM, Maj M, Baune BT, Mitchell PB, Vieta E, Frye MA, Rybakowski JK, Kuo PH, Kato T, Grigoroiu-Serbanescu M, Reif A, Del Zompo M, Bellivier F, Schalling M, Wray NR, Kelsoe JR, Alda M, McMahon FJ, Schulze TG, Rietschel M, Nöthen MM, and Cichon S

Abstract

Bipolar disorder (BD) is a common, highly heritable neuropsychiatric disease characterized by recurrent episodes of mania and depression. Lithium is the best-established long-term treatment for BD, even though individual response is highly variable. Evidence suggests that some of this variability has a genetic basis. This is supported by the largest genome-wide association study (GWAS) of lithium response to date conducted by the International Consortium on Lithium Genetics (ConLiGen). Recently, we performed the first genome-wide analysis of the involvement of miRNAs in BD and identified nine BD-associated miRNAs. However, it is unknown whether these miRNAs are also associated with lithium response in BD. In the present study, we therefore tested whether common variants at these nine candidate miRNAs contribute to the variance in lithium response in BD. Furthermore, we systematically analyzed whether any other miRNA in the genome is implicated in the response to lithium. For this purpose, we performed gene-based tests for all known miRNA coding genes in the ConLiGen GWAS dataset ( n = 2,563 patients) using a set-based testing approach adapted from the versatile gene-based test for GWAS (VEGAS2). In the candidate approach, miR-499a showed a nominally significant association with lithium response, providing some evidence for involvement in both development and treatment of BD. In the genome-wide miRNA analysis, 71 miRNAs showed nominally significant associations with the dichotomous phenotype and 106 with the continuous trait for treatment response. A total of 15 miRNAs revealed nominal significance in both phenotypes with miR-633 showing the strongest association with the continuous trait ( p = 9.80E-04) and miR-607 with the dichotomous phenotype ( p = 5.79E-04). No association between miRNAs and treatment response to lithium in BD in either of the tested conditions withstood multiple testing correction. Given the limited power of our study, the investigation of miRNAs in larger GWAS samples of BD and lithium response is warranted.

Published
2018
Full Text
View/download PDF

7. Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report.

Author

Manchia M, Adli M, Akula N, Ardau R, Aubry JM, Backlund L, Banzato CE, Baune BT, Bellivier F, Bengesser S, Biernacka JM, Brichant-Petitjean C, Bui E, Calkin CV, Cheng AT, Chillotti C, Cichon S, Clark S, Czerski PM, Dantas C, Zompo MD, Depaulo JR, Detera-Wadleigh SD, Etain B, Falkai P, Frisén L, Frye MA, Fullerton J, Gard S, Garnham J, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Heilbronner U, Hoban R, Hou L, Jamain S, Kahn JP, Kassem L, Kato T, Kelsoe JR, Kittel-Schneider S, Kliwicki S, Kuo PH, Kusumi I, Laje G, Lavebratt C, Leboyer M, Leckband SG, López Jaramillo CA, Maj M, Malafosse A, Martinsson L, Masui T, Mitchell PB, Mondimore F, Monteleone P, Nallet A, Neuner M, Novák T, O'Donovan C, Osby U, Ozaki N, Perlis RH, Pfennig A, Potash JB, Reich-Erkelenz D, Reif A, Reininghaus E, Richardson S, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schubert OK, Schweizer B, Seemüller F, Grigoroiu-Serbanescu M, Severino G, Seymour LR, Slaney C, Smoller JW, Squassina A, Stamm T, Steele J, Stopkova P, Tighe SK, Tortorella A, Turecki G, Wray NR, Wright A, Zandi PP, Zilles D, Bauer M, Rietschel M, McMahon FJ, Schulze TG, and Alda M

Subjects
Antimanic Agents therapeutic use, Female, Humans, International Cooperation, Lithium Compounds therapeutic use, Male, Models, Theoretical, Phenotype, Reproducibility of Results, Treatment Outcome, Antimanic Agents administration & dosage, Bipolar Disorder drug therapy, Lithium Compounds administration & dosage
Abstract

Objective: The assessment of response to lithium maintenance treatment in bipolar disorder (BD) is complicated by variable length of treatment, unpredictable clinical course, and often inconsistent compliance. Prospective and retrospective methods of assessment of lithium response have been proposed in the literature. In this study we report the key phenotypic measures of the "Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder" scale currently used in the Consortium on Lithium Genetics (ConLiGen) study., Materials and Methods: Twenty-nine ConLiGen sites took part in a two-stage case-vignette rating procedure to examine inter-rater agreement [Kappa (κ)] and reliability [intra-class correlation coefficient (ICC)] of lithium response. Annotated first-round vignettes and rating guidelines were circulated to expert research clinicians for training purposes between the two stages. Further, we analyzed the distributional properties of the treatment response scores available for 1,308 patients using mixture modeling., Results: Substantial and moderate agreement was shown across sites in the first and second sets of vignettes (κ = 0.66 and κ = 0.54, respectively), without significant improvement from training. However, definition of response using the A score as a quantitative trait and selecting cases with B criteria of 4 or less showed an improvement between the two stages (ICC1 = 0.71 and ICC2 = 0.75, respectively). Mixture modeling of score distribution indicated three subpopulations (full responders, partial responders, non responders)., Conclusions: We identified two definitions of lithium response, one dichotomous and the other continuous, with moderate to substantial inter-rater agreement and reliability. Accurate phenotypic measurement of lithium response is crucial for the ongoing ConLiGen pharmacogenomic study.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results